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The role of CD19 CD5 and CD19 CD5 B cell subpopulations in the antibody response to pneumococcal capsular polysac-
charides (caps-PSs) is controversial. In the present study, we evaluated the role of human CD19 CD5 and CD19 CD5 cell
populations in the serotype-specific antibody response to caps-PS. After vaccination of 5 healthy human adults with Pneumovax
(23-valent pneumococcal polysaccharide vaccine [PPV23]), IgG anti-caps-PS serotype 4 antibody-producing cells resided mainly
in the CD19 CD5 B cell subset, as assessed by enzyme-linked immunosorbent spot (ELISpot) analysis. Moreover, in a human-
ized SCIDmouse model, CD19 CD5 B cells were more effective than CD19 CD5 cells in producing IgG anti-cap-PS anti-
bodies. Finally, an association was found between the level of IgG anti-caps-PS antibodies and the number of CD19 CD5 B
cells in 33 humans vaccinated with PPV23. Taken together, our data suggest that CD5 defines a functionally distinct population
of B cells in humans in the anti-caps-PS immune response.
Infections caused by Streptococcus pneumoniae (e.g., pneumonia,septicemia, andmeningitis) are an important cause of mortality
and morbidity, especially among young children, the elderly, and
immunocompromised patients. Host protection against pneu-
mococcal infections ismediated by antibodies (Abs) against pneu-
mococcal surface proteins and capsular polysaccharides (caps-
PSs) (1). Caps-PSs are a main determinant of virulence of S.
pneumoniae, and antibodies to caps-PS, which are considered T
lymphocyte-independent type 2 antigens, are protective against
infection with S. pneumoniae. In mice, antibodies to T lympho-
cyte-independent antigens have been demonstrated to be gener-
ated by a distinctive B lymphocyte population, the so-called B-1
lymphocytes (2). B-1 lymphocytes represent a unique B-cell pop-
ulation that can be differentiated from marginal zone B cells and
follicular B cells (together referred to as B-2 cells) by surface
marker expression, developmental origin, self-renewing capacity,
and functions (2). Furthermore,murine B-1 cells can be separated
phenotypically into two functionally different subpopulations on
the basis of surface expression of CD5. The CD5 subset (referred
to as B-1a cells) is responsible for the constitutive secretion of
polyspecific antibodies (mainly IgM), whereas the CD5 subset
(B-1b cells) produces antibodies (IgM, IgA, and IgG isotype) only
after antigen-specific stimulation, including stimulation with
caps-PS antigens of S. pneumoniae (3, 4).
In humans, the existence of B-1 cells has been open to question
formany years. Recently, Griffin et al. (5) claimed the discovery of
a small subset of human CD20 B cells expressing CD27 and
CD43 that recap the functional characteristics ofmurine B-1 cells.
However, controversy has arisen about the nature of these cells,
and we recently showed that CD27 CD43 B cells are in fact
activated cells on their way to plasma cell differentiation (6–9).
We recently evaluated whether CD20 CD27 CD43 B cells
are involved in antibody production in response to pneumococcal
caps-PS and found that the numbers of these cells increased in
peripheral blood 1 week after vaccination with unconjugated
pneumococcal polysaccharide vaccine (PPV23) (8). Interestingly,
enzyme-linked immunosorbent spot (ELISpot) analysis of iso-
lated cell populations revealed that the CD5 subset of these cells
had a higher capacity than the CD5 subset for the production
caps-PS-specific antibodies (particularly IgG) (8). This finding (8)
is in line with data from an older study by Barrett et al., who found
that anti-type 4 pneumococcal polysaccharide antibody-secreting
cells were found in the CD5 B cell subpopulation (10). Further-
more, the importance of the CD5 subset of B cells for antibody
production in response to polysaccharide antigens is also sug-
gested by peripheral blood CD5 B cell predominance in patients
with a specific antipolysaccharide antibody deficiency (11).
Taken together, the above-summarized data suggest a func-
tional role of CD5 B cells in the antibody response to caps-PS.
However, the concept that CD5 defines a functionally distinct
population of B cells in the human anti-caps-PS immune response
is not generally accepted. Carsetti et al. assert that human IgM
memory B cells that are generated in the spleen control the im-
mune response to pneumococcal caps-PS and claim that CD5
does not define a functionally distinct population of B cells in the
human anti-caps-PS response (12, 13).
Given the controversial nature of this subject, we sought to
further delineate the role of the CD19 CD5 and CD19 CD5
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B cell subpopulations in the human antibody response to pneu-
mococcal caps-PS. In order to realize this, we performed studies
with humans and humanized SCID mice.
MATERIALS AND METHODS
Subjects. Thirty-three patients (median age, 4 years; age range, 2 to 41
years) who were referred (between 2008 and 2010) to our institution for
increased susceptibility to respiratory infections were included in this
study. Recurrent infection of the upper respiratory tract was defined as at
least 5 episodes of upper respiratory tract infections complicated by otitis
media or chronic draining ears (3 weeks) in a 1-year period. Recurrent
infection of the lower respiratory tract was defined as at least 3 lower
respiratory tract infections in a 1-year period, with radiographic evidence
of pneumonia in at least 2 episodes. These patients were immunized with
a 23-valent pneumococcal polysaccharide vaccine (PPV23) (Pneumovax;
SanofiMSD) for evaluation of the humoral immune system as part of the
clinical workup. Children (aged 2 to 5 years) had received a conjugated
pneumococcal vaccine (Prevnar 7; Pfizer) during their first year of life.
Five healthy adults (laboratory workers and students) were immu-
nized with PPV23 specifically for this study, which was approved by the
ethics committee of the University Hospital Leuven. Seven days after im-
munization, blood was taken and analyzed by ELISpot analysis.
Detectionof anti-caps-PSantibody-secreting cells byELISpot assay.
A caps-PS-specific ELISpot assay was performed as previously described
by Mascart-Lemone et al. (14), with slight modifications. In brief, indi-
vidual wells of a nitrocellulose Millititer HA plate (Mahans 4550; Milli-
pore) were coated overnight at 4°C in a humid chamber with 100 l of a
poly-L-lysine hydrobromide (molecular weight [MW], 30,000 to 70,000;
Sigma)-coupled caps-PS-specific antigen solution. A total of 5  104
sorted B cells were applied per well.
Mice. CB17 PrkdcSCID/PrkdcSCID (SCID) mice (Jackson Labora-
tory) were bred under sterile conditions and fed ad libitum with auto-
claved food and water. SCID mice were held in a room with a 12-h/12-h
light/dark cycle. SCIDmice were tested for leakiness by analyzing the level
of mouse IgG Abs according to a previously described enzyme-linked
immunosorbent assay (ELISA) (15). Only 6- to 10-week-old SCID mice
with IgG concentrations of2 g/ml were used in the experiments. Ap-
proval of this study was granted by the KU Leuven ethics committee for
animal experiments.
Isolation of PBMCs and cell subsets. Peripheral blood buffy coat
from healthy blood donors was obtained from the Blood Transfusion
Centre of the Red Cross Flanders. No information about previous expo-
sure of human donors to any particular S. pneumoniae serotype was avail-
able, nor was the vaccination status of the blood donors known. Human
peripheral blood mononuclear cells (PBMCs) were prepared by Ficoll-
Hypaque density gradient centrifugation. The viability of human PBMCs
(99%) was tested by trypan blue exclusion. Enriched CD19 B cells
(obtained with CD19 human microbeads) were stained with anti-CD5
allophycocyanin (cloneUCHT2) orwith an isotype control (mouse IgG1)
(4°C for 30 min) and sorted on a FACSAria cell sorter (BD Biosciences)
under sterile conditions.
Cell transfer experiments and in vivo immunization. SCID mice
were treated intraperitoneally (i.p.) with 1mgTM1 1 day before human-
ization to improve human cell engraftment (16). Anti-NK-treated SCID
mice were immunized i.p. with 20 l of PPV23 at the same time as they
received the human cells. The CD19/CD4 ratio of the cells transferred
corresponded to the CD19/CD4 ratio in the donor buffy coat. Four-
teen days later, blood was drawn by heart puncture in isoflurane (Scher-
ing-Plough Animal Health)-anesthetized mice. Mice were euthanized by
cervical dislocation after isoflurane inhalation.
Detection of caps-PS-specific Ig by ELISA. Antibodies to cap-PS se-
rotypes weremeasured by an ELISA, as previously described (17, 18). Sera
were preabsorbed with C polysaccharide and serotype 22F to remove
cross-reactive antibodies before application onto coated plates. For each
sample, six 2-fold dilutions (starting from a 1:200 dilution for serum from
humans and a 1:6.25 dilution for sera from humanized mice) were ana-
lyzed. For quantification of anti-caps-PS antibodies, U.S. pneumococcal
reference serum lot 89-SF was used as a reference. For calculation of the
concentration, a 4-parameter logistic-log curve fit model was used.
Opsonophagocytic activity. Opsonophagocytic activity was deter-
mined for serotypes 18C, 19F, 6A, and 9V by a 4-fold multiplex op-
sonophagocytosis assay (19). Titers were expressed as serum dilutions
with 50% killing of the given serotype. A titer below the detection limit of
8 was reported as 4 for the purpose of data analyses.
Statistical methods. Statistical tests were performed by using Ana-
lyze-it forMicrosoft Excel 3.90. AWilcoxon-Mann-Whitney test was used
to evaluate differences in antibody-secreting cells (betweenCD19CD5
andCD19CD5). Differences in antibody responses and opsonophago-
cytic activity betweenCD19CD5B cells andCD19CD5B cells were
evaluated by use of a Kruskal-Wallis test (significance level, 5%). Corre-
lations between antibody titers and opsonophagocytic activity and be-
tween anti-caps-PS antibody responses and the amount of CD19 CD5
B cells were evaluated by use of the Spearman correlation (significance
level, 5%).
RESULTS
We vaccinated five healthy adults with PPV23 and evaluated the
capacity of CD19 CD5 and CD19 CD5 B cells to secrete
serotype 4 caps-PS-specific antibodies by an ELISpot assay 7 days
after vaccination. Serotype 4 was selected, as this serotype was
previously used for ELISpot analysis (8, 10). Although there was a
substantial variation in the number of antibody-secreting cells
among the five individuals (summarized in Table 1), the number
of IgG antibody-secreting cells consistently tended to be higher in
the CD19 CD5 cell subset than in the CD19 CD5 cell subset
(P 	 0.06 by Wilcoxon test). The numbers of IgM anti-caps-PS
serotype 4 antibody-secreting cells were comparable between the
two subsets (P 	 0.8 by Wilcoxon test). Figure 1 illustrates the
results from one representative individual. No anti-caps-PS anti-
body-secreting cells were found before vaccination (data not
shown).
To evaluate the role of CD19CD5 and CD19CD5 B cells
further, we used a humanized SCIDmouse model. TM1-treated
SCID mice were transplanted i.p. with PBMCs (containing 20 
106 
 4.0  106 CD4 cells) depleted of B lymphocytes in com-
binationwith eitherCD19CD5 enrichedB cells (2 106 to 3
106 cells; average purity, 79% CD19 CD5) or CD19 CD5
enriched B cells (containing 2  106 to 3  106 cells; average
purity, 95%). Two weeks after immunization with a reduced dose
of PPV23 (20l; two-fifths of the dose used in humans), antibod-
ies to serotypes 1, 3, 4, 18C, and 19F were measured by an ELISA.
TABLE 1 Capacity of CD19 CD5 and CD19 CD5 cells to secrete
caps-PS-specific antibodies after vaccinationa
Healthy
individual
No. of cells secreting IgG No. of cells secreting IgM
CD19 CD5 CD19 CD5 CD19 CD5 CD19 CD5
1 298 57 31 19
2 119 31 14 20
3 4 1 3 1.5
4 52 45 25 19
5 31 24 27 31
a Five healthy individuals were vaccinated with PPV23. The capacity of CD19 CD5
and CD19 CD5 cells to secrete caps-PS-specific antibodies was evaluated by ELISpot
analysis 7 days after vaccination. Shown are the numbers of IgG and IgM anti-caps-PS
serotype 4 antibody-secreting cells per 2.5 104 cells for the CD19 CD5 and CD19
CD5 subsets.
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These serotypes were selected because they are immunogenic (20)
and have been prevalent in Belgium over the last 15 years (21, 22).
SCID mice reconstituted with CD19 CD5 B cells produced
significantly higher levels of IgG antibodies than did SCID mice
reconstituted with CD19 CD5 B cells (Fig. 2). The IgM anti-
body responsewas low and comparable betweenCD5 andCD5
cells (data not shown). Immunized SCID mice that had not been
transplanted generated no antibodies (data not shown). Thus,
CD19CD5 B cells were more effective than CD19CD5 cells
for IgG antibody production.
In order to evaluate the functional activity of the antibodies
produced, we studied opsonophagocytosis in SCIDmice reconsti-
tuted with either CD19 CD5 B cells or CD19 CD5 B cells.
While our focus was on serotypes 18C and 19F, for which we had
ELISA values, the assaywasmultiplexedwith serotypes 6A and 9V.
Analysis of opsonophagocytosis of additional serotypes was ham-
pered by the limited serumvolumes available from the humanized
SCID mice. The level of opsonophagocytosis was low in SCID
mice reconstituted with CD19 CD5 B cells. In SCID mice re-
constituted with CD19 CD5 B cells, the level of opsonophago-
cytosis tended to be higher than those in SCIDmice reconstituted
with CD19 CD5 B cells for caps-PS serotype 18C (P 	 0.06),
caps-PS serotype 6A (P 	 0.12), and caps-PS serotype 19F (P 	
0.28) but not for caps-PS serotype 9V (P	 0.98 by Kruskal-Wallis
test) (Fig. 3). For caps-PS serotype 18C, there was a statistically
significant correlation between opsonophagocytosis and IgG ti-
ters (Pearson correlation coefficient [rs], 0.689;P	0.0001). For
caps-PS serotype 19F, the Pearson correlation coefficient was
0.321 (P	 0.09).
Based on the above-described data, we hypothesized that indi-
viduals with high numbers of CD19 CD5 cells generate more
IgG antibodies to soluble caps-PS than do individuals with low
FIG 1 Caps-PS antibody secretion by CD19 CD5 and CD19 CD5 B cell subsets after vaccination with PPV23. CD19 CD5 B cells (2.5 104/well) and
CD19 CD5 B cells (2.5 104/well) obtained from a healthy adult at 7 days post-PPV23 vaccination were analyzed for their capacity to secrete anti-caps-PS
serotype 4 antibodies by an ELISpot assay. ASC, antibody-secreting cells.
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numbers of CD19 CD5 B cells. In order to test this hypothesis,
we prospectively quantified CD19 CD5 cells in 33 individuals
vaccinated with PPV23. These children and young adults were
being investigated for frequent infections, and their characteristics
(age and sex) are described in Table 2. The numbers of CD19
CD5 B cells and the IgG response to pneumococcal polysaccha-
rides were measured 3 weeks after vaccination with PPV23. For
these studies, data from the laboratory clinical immunological in-
vestigation were used. This included data on antibodies to sero-
type 3 (strong immunogen), serotype 4 (intermediate immuno-
gen), and serotype 9N (low immunogen) (18). The results are
shown in Fig. 4. There was a correlation (Spearman) between the
numbers of CD19 CD5 cells and the postvaccination IgG anti-
body levels for serotype 3 (rs, 0.336; P 	 0.056), serotype 4 (rs,
0.535; P	 0.0013), and serotype 9N (rs, 0.626; P	0.0001).
Data on prevaccination antibody levels were available for 26
patients for serotype 3 and serotype 9N and for 27 patients for
serotype 4. The vaccination-induced fold increase of the specific
antibody level (postvaccination antibody level divided by the pre-
vaccination antibody level) was calculated and correlated with the
FIG 2 Effect of B-cell subsets on the IgG antibody response to soluble caps-PS. SCID mice were transplanted with PBMCs depleted of CD19 B cells in
combination with either CD5 B lymphocytes or CD5 B lymphocytes and immunized with soluble caps-PS (PPV23). The immune response to caps-PS
(serotypes 1, 3, 4, 18C, and 19F) wasmeasured after 14 days. Data from five independent experiments (n	 7 for CD5; n	 21 for CD5) were pooled. For each
experiment, theCD5 andCD5B lymphocytes came froma single individual (five independent experimentswith cells obtained fromfive different individuals).
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number of CD19CD5 cells. There was a significant correlation
(Spearman) between the number of CD19 CD5 cells and the
fold increase of IgG antibody levels for serotype 3 (rs, 0.462; P	
0.0175), serotype 4 (rs, 0.446; P	 0.00198), and serotype 9N (rs,
0.567; P	 0.0025).
There was also a significant correlation between the total num-
ber of B lymphocytes and the number of CD5 B cells (rs, 0.735;
P	0.0001).
Analysis of patients 5 years old (n 	 22) (who received a
conjugated pneumococcal vaccine during their first year of life)
also revealed a significant correlation between the numbers of
CD19 CD5 cells and the postvaccination IgG antibody levels
for serotype 4 (rs, 0.523;P	 0.015) and serotype 9N (rs, 0.643;P	
0.0017). For serotype 3, the correlation (rs) was 0.345 (P	 0.125).
For subjects 5 years old, no significant correlation was found
(P  0.5), probably because of the limited number of subjects
included (n	 11).
DISCUSSION
The role of the CD19 CD5 and CD19 CD5 B cell subpopu-
lations in the antibody response to caps-PS is controversial. In the
present study, we evaluated the role of the CD19 CD5 and
CD19 CD5 B cell subpopulations in the antibody response to
caps-PS using three approaches.
First, we found that after vaccination with PPV23, the IgG
anti-caps-PS serotype 4 antibody-producing cells in healthy
adults residedmainly in the CD19CD5B-cell subset. This con-
firms a previously reported observation that anti-type 4 pneumo-
FIG 3 Effect of B cell subsets on opsonophagocytic activity. SCID mice were transplanted with PBMCs depleted of CD19 B cells in combination with either
CD5 B lymphocytes or CD5 B lymphocytes and immunized with soluble caps-PS (PPV23). The opsonophagocytic activity in response to caps-PS serotypes
18C, 19F, A, and 9Vwasmeasured after 14 days. Data fromfive independent experiments (n	 7 for CD5; n	 21 for CD5) were pooled. For each experiment,
the CD5 and CD5 B lymphocytes came from a single individual (five independent experiments with cells obtained from five different individuals). The y axis
represents titers expressed as serum dilutions with 50% killing.
Antipolysaccharide Antibody Response and CD5 B Cells
July 2015 Volume 83 Number 7 iai.asm.org 2893Infection and Immunity
 o
n
 January 15, 2016 by 26989832
http://iai.asm
.org/
D
ow
nloaded from
 
coccal polysaccharide antibody-secreting cells were found in the
CD5 B cell subpopulation (10) and is consistent with our recent
observation that the CD5 fraction of CD20 CD27 CD43 B
cells generated anti-caps-PS serotype 4 antibodies (8).
Second, in a humanized mouse model, IgG anti-caps-PS anti-
bodies (for serotypes 1, 3, 4, 18C, and 19F) derived mainly from
CD19 CD5 cells. Since the main mechanism by which anti-
caps-PS antibodies confer protection is through activation of the
complement system and opsonization for phagocytosis (23), we
also measured opsonophagocytic activity of the antibodies pro-
duced by the humanized mice. Levels of opsonophagocytic activ-
ity for caps-PS serotypes 18C, 6A, and 19F, but not serotype 9V,
tended to be higher in SCID mice reconstituted with CD19
CD5 B cells than in SCIDmice reconstituted with CD19CD5
B cells, although this differencewas not statistically significant and
serotype dependent. The dynamic range of the opsonophagocyto-
sis assay is lower than the dynamic range of ELISAs. This could
explain why the ELISA better discriminated between the antibody
responses of CD5 and CD5 cells in a humanized SCID model.
Finally, we found an association between the number of
CD19 CD5 B cells and the level of IgG anti-caps-PS antibodies
or the fold increase of the specific antibody level in individuals
immunized with PPV23. This association was found for the three
serotypes tested (serotypes 3, 4, and 9N), independent of whether
the serotype was included in the conjugated vaccine or not. The
young children (aged 2 to 5 years) included in our study had
received a conjugated pneumococcal vaccine (Prevnar 7) during
their first year of life. This might affect the subsequent antibody
response to PPV23 for serotype 4, which is contained within the
conjugated vaccine, but not for serotypes 3 and 9N (not contained
within the conjugated 7-valent vaccine). Analysis of the subgroup
of children younger than 5 years of age revealed a statistically
significant correlation between the number of CD19 CD5 B
cells and the antibody level for serotype 4 and serotype 9N. It
should be noted that these studies were performed on patients
with a history of frequent infection.
We used different approaches to study the role of CD5 B cells
in the anti-caps-PS antibody response. Although the serotypes
tested were not fully consistent across the different approaches,
the overall results largely indicate that for several serotypes, the
antibody response was dependent on CD19 CD5 human B
cells.
Although it has been suggested that CD5 does not define a
functionally distinct population of B cells in the human anti-
caps-PS response (12, 13), our data argue in favor of the idea that
CD19 CD5 characterizes a functionally separate population of
B cells in the human serotype-specific IgG anti-caps-PS immune
response. Our data therefore confirm previous suggestions that
theremay be an association betweenCD19CD5B cell predom-
inance and specific antipolysaccharide deficiency (10) and that
human IgG caps-PS-secreting cells bear the CD19CD5 pheno-
type (8). Serotype-dependent differences, however, may exist.
Under conditions of pneumococcal disease susceptibility, di-
minished numbers of CD5 B cells could be a possible basis for
immunodeficiency. For example, it has been reported that the
number of CD19 CD5 B cells was lower in patients with com-
TABLE 2 Age and sex distribution of patients vaccinated with PPV23
Patient characteristic No. of patients
Age (yr)
2 5
3 9
4 6
5 1
7 2
8 4
9 3
11 1
35 1
41 1
Sex
Male 17
Female 16
FIG 4 Antibody response to PPV23 as a function of CD5 B cell subset.
Thirty-three individuals suffering from increased susceptibility to respiratory
infections were vaccinated with PPV23. The IgG antibody response to caps-PS
serotype 3 (top), caps-PS serotype 4 (middle), and caps-PS serotype 9N (bot-
tom) was measured 3 weeks after vaccination. Shown is the antibody level (y
axis) as a function of the number of CD19 CD5 B cells.
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mon variable immunodeficiency than in controls (24). Moreover,
HIV-infected patients, who have a high risk of pneumococcal dis-
ease (25), have a striking increase in the percentage of CD5 B
lymphocytes (54.7%
 19% of circulating B cells) compared with
HIV-negative drug users (35.5%  14%) and with healthy con-
trols (17%
 5%) (26).
The CD5 B cell population is prominent in early life, and the
percentage of CD5 B cells diminishes with age (27). Human B
cells gradually lose CD5 and acquire CD27 during maturation
from immature transitional cells viamature naive cells tomemory
cells (28). CD5 B cells have fewer somatic hypermutations than
do CD5 B cells and predominantly produce spontaneous low-
affinity IgM Abs (29, 30). CD5 expression probably denotes im-
mature/naive B cells. The relative absence of CD5 B cells in
young infants could be a reason why young children do not re-
spond to pneumococcal polysaccharides until they are older.
Taken together, one could hypothesize that a predominance of
CD5 B cells and a lack of CD5 B cells are associated with sus-
ceptibility to pneumococcal disease.
In conclusion, the results described in this report implicate a
role for the CD19 CD5 cell population in the human IgG anti-
body response to pneumococcal caps-PS.
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